Semaphorins, specifically type IV, are important regulators of axonal guidance and 48 have been increasingly implicated in poor prognoses in a number of different solid 49 cancers. In conjunction with their cognate PLXNB family receptors, type IV members have 50 been increasingly shown to mediate oncogenic functions necessary for tumor 51 development and malignant spread. In this study, we investigated the role of semaphorin 52 4C (SEMA4C) in osteosarcoma growth, progression, and metastasis. We investigated 53 the expression and localization of SEMA4C in primary osteosarcoma patient tissues and 54 its tumorigenic functions in these malignancies. We demonstrate that overexpression of 55 SEMA4C promotes properties of cellular transformation, while RNAi knockdown of 56 SEMA4C promotes adhesion and reduces cellular proliferation, colony formation, 57 migration, wound healing, tumor growth, and lung metastasis. These phenotypic changes 58 were accompanied by reductions in activated AKT signaling, G1 cell cycle delay, and 59 decreases in expression of mesenchymal marker genes SNAI1, SNAI2, and TWIST1. 60
Furthermore, activation of downstream signaling processes that involve the MAP 92 kinase/PI3K pathways through heterodimerization with other receptor tyrosine kinases 93 (RTKs) such as MET (MET proto-oncogene, receptor tyrosine kinase) and/or ERBB2 94 (erb-b2 receptor tyrosine kinase 2) can potentiate many of the invasive cellular processes 95 associated with solid cancers [13] . SEMA4C, a type IV semaphorin, and its cognate 96 receptor PLXNB2, have been recently characterized as oncogenic signaling partners in 97 invasive breast cancer [14] , hepatocellular carcinoma [15] , and glioma [16] . Moreover, 98 SEMA4C has been shown to play diverse roles in the propagation of pain signaling [17] , 99 as well as in the immune system during Th2-driven immune responses similar to other 100 semaphorin IV family members [18] . 101
Here, we studied SEMA4C's role in osteosarcoma growth and metastasis. We 102
show that 1) SEMA4C is upregulated in a subset of osteosarcoma patient samples and 103 cell lines; 2) high SEMA4C expression enhances properties of cellular transformation, 104 mesenchymal marker expression, and that genetic knockdown conversely reduces those 105 phenotypes/markers; 3) SEMA4C modulates osteosarcoma growth and lung metastasis 106 and 4) targeted monoclonal antibody blockade of SEMA4C robustly reduces these 107 phenotypes associated with high-level SEMA4C expression. Together, this study 108 expands upon the current known functions of SEMA4C in a highly malignant pediatric 109 solid cancer and suggests that antibody blockade of SEMA4C-PLXNB2 signaling may 110 overcome the current hurdles for targeting pathways that ultimately lead to metastatic 111 lung nodule formation and continued disease progression. 112 113 2. Materials and Methods 114 2.1 RNA sequencing data sets 115 SEMA4C expression levels in normal human osteoblasts and human 116 osteosarcoma patient samples were analyzed from an existing data set [11] . 117 118 2.2 Tissue microarray (TMA) samples and scoring 119
The osteosarcoma tissue microarray was purchased from Biomax (Osteosarcoma: 120
OS804c) containing 40 samples in duplicate. Slides containing 4 μm thick formalin-fixed, 121 paraffin-embedded sections of tumor tissue were deparaffinized and rehydrated. Antigen 122 retrieval was performed in a steamer using 1 mM Tris base EDTA buffer, pH 9.0. After 123 endogenous peroxidase blocking, a protein block was applied. Immunohistochemistry 124 (IHC) for SEMA4C was performed using a rabbit anti-SEMA4C primary antibody 125 (#AF6125, R & D Systems) on an autostainer (Dako). Detection was achieved using the 126 Envision rabbit detection system (Dako) with diaminobenzidine (DAB) as the chromogen. 127
Tissue sections were imaged on a Nikon E800M microscope at 40X magnification using 128 a Nikon DSRi2 camera and Nikon Elements D Version 4 software. Slides were evaluated 129 and scored as previously described [19] . 130 grown in RPMI-1640. NHOs were grown in aMEM. Osteosarcoma cell line media was 138 fortified with 10% fetal bovine serum (FBS) and 1X penicillin/streptomycin and NHO 139 media was fortified with 20% FBS and 1X penicillin/streptomycin. HUVECs were cultured 140 with EGM-2 bullet kit media (#cc-3162, Lonza) with 1X antibiotic-antimycotic (#15240062, 141
Thermo Fisher) in cell culture flasks coated with 1% gelatin (#G1383, Sigma Aldrich).. All 142 cell cultures were incubated in a water-jacketed incubator set at 5% carbon dioxide (CO2) 143 and at 37°C. All cell lines except NHO, G-292, and HUVECs were authenticated by the 144 University of Arizona Genetics Core (UAGC) using short tandem repeat profiling. All cell 145 lines were found to be free from mycoplasma. 146 147
Generation of shRNA knockdown and overexpression cell lines 148
Stable knockdown of SEMA4C was accomplished with pGIPZ lentiviral vectors 149 expressing an shRNA against SEMA4C in conjunction with GFP and a puromycin 150 selection marker (sh1 #V3LHS_394644, sh2 #V3LHS_413698, Open Biosystems). 151
Control pGIPZ vector with non-targeting shRNA was used as a control (#RHS4346, Open 152 Biosystems). Lentiviral particles were produced with 293T cells co-transfected with pGIPZ 153 shRNAs, pMD2.G envelope (#12259, addgene) and psPAX2 (#12260, addgene) 154 packaging vectors. Stable shRNA knockdown lines were established via puromycin 155 selection at 1 µg/mL. Overexpression vectors were generated using the human SEMA4C 156 cDNA sequence (#40035253, Dharmacon) and vectors/cell lines were established using 157 previously described methodology [20, 21] . 158
Anti-SEMA4C or isotype control antibody was administered at 10 µg/mL and 15 161 µg/mL where indicated (#sc-136445, Santa Cruz Biotechnology 
MTS cellular proliferation assay 191
Cellular proliferation assays were performed as previously described [11] . Briefly, 192 Wound healing assays were performed as previously described [20] . Briefly, 1 x 207 10 4 cells were plated into a removable 2-well silicone culture insert which generated a 208 defined cell-free gap (ibidi). Cells were then incubated for 24 hours before inserts were 209 removed and fresh cell culture media was added. Phase contrast images of the wounds 210 were acquired every 10 minutes for 16-20 hours, which was sufficient for the cells to 211 completely close the simulated wound gap. A custom-written image segmentation 212 algorithm in MATLAB was used to measure wound distance over time and to calculate 213 closure rate. 214 215
3D microfluidic cellular adhesion assay 216
Cellular adhesion assays were performed as previously described [22] . Briefly, the 217 microfluidic model was fabricated using standard soft lithography of polydimethylsiloxane 218 (PDMS) (#4019862, Ellsworth). Rat tail collagen I (#CD354249, Corning) was buffered 219 with PBS and cell culture grade water to create a 6 mg/mL solution. Collagen was then 220 loaded into the lower channel of the microfluidic model and allowed to nucleate at 37°C 221 for at least 1 hour. The upper channel was coated with 1% gelatin solution for 30 minutes 222 at room temperature. HUVECs were released using trypsin, resuspended in a 4% w/v 223 dextran (#31392, Sigma Aldrich) solution in EGM-2 media at a concentration of 224 approximately 1 x 10 6 cells per mL, and 50 µL of the cell solution was added to the inlet 225 of the microfluidic model. HUVECs become confluent in the channel over 24-48 hours at 226 37°C. 5 x 10 4 green fluorescent protein (GFP)-expressing osteosarcoma cells were then 227 added to the inlet of the model and allowed to adhere over 3 hours. Microfluidic models 228 were imaged at 24 hours. Adhesion and invasion of osteosarcoma cells was quantified. 229
Soft agar colony formation assay 231
Modified cells (1 x 10 4 ) were seeded into a 0.35% agar solution placed on top of a 232 0.5% agar in six-well plates and allowed to incubate for 2-3 weeks. The resultant colonies 233 were fixed, divided into four quadrants, and imaged using microscopy. Colonies were 234 quantified via ImageJ v1.52a software using a standard colony quantification macro [11] . Quantification of nodule number and area was undertaken in 9 sections from four 256 mice/group (shCON and shSEMA4C) at 4X using ImageJ v1.52a software. 257 258
Statistical analysis 259
All statistical analyses were performed using Prism v8 software (GraphPad). All 260 data are presented as mean ± standard error of the mean (SEM). Two groups were 261 compared using a two-tailed unpaired Student's t-test. Three or more groups were 262 compared using a One-way ANOVA with Bonferroni's post hoc or Two-way ANOVA 263 analyses were performed and followed with Bonferroni's post hoc testing. All statistical 264 analyses are individually indicated where applied throughout. In all cases, p < 0.05 was 265 considered statistically significant. 266 267
Results 268

SEMA4C is highly expressed in some osteosarcoma tissues and cell lines 269
In order to investigate the potential role of SEMA4C in osteosarcoma development 270 and metastasis, we first examined SEMA4C mRNA expression in 12 human shRNA knockdown was evaluated via qRT-PCR (Fig. 3A , **p < 0.01, ****p < 0.0001) and 321 western blot (Fig. 3B ). Following evaluation, shRNA #2 was chosen for both lines in all 322 subsequent experiments. Knockdown of SEMA4C reduced cellular proliferation (Fig. 3C , 323 ****p < 0.0001) and colony formation (Fig. 3D , ****p < 0.0001) in both lines. These 324 reductions in 2D and 3D growth were accompanied by downregulation of activated AKT 325 signaling (Fig. 3E) . Lastly, silencing of SEMA4C was associated with G1 cell cycle delay 326 in both lines (Fig. 3F , *p < 0.05, **p < 0.01). Silencing of SEMA4C did not induce cleaved 327 CASP3 activity (Supp. Figs. 2A and 2B ). Together, these data suggest SEMA4C 328 modulates cellular growth and colony formation in osteosarcoma cell lines. 329
330
SEMA4C promotes cellular motility and loss of adhesion 331
Next, we examined the role of SEMA4C in cellular movement using migration 332 chambers, wound healing assays, and 3D microfluidic chambers. Knockdown Lastly, we sought to evaluate the therapeutic potential of SEMA4C blockade using 372 a commercially available monoclonal antibody raised against amino acids 400-510 of 373 human SEMA4C. To evaluate the effects of blockade in vitro, we treated wild-type normal 374 human osteoblasts (NHO), HOS, and SJSA-1 osteosarcoma cells with two concentrations 375 of anti-SEMA4C or isotype control IgG and assayed its effects on cellular proliferation. 376
Reduced cellular proliferation was observed following a 48-hour treatment in both 377 osteosarcoma cell lines, but not NHOs (Fig. 6A , ****p < 0.0001). Similarly, treatment with 378 anti-SEMA4C also reduced migration in both osteosarcoma cell lines (Fig. 6B , ****p < 379 0.0001). Representative images are shown in Fig. 6C . Following treatment, G1 cell cycle 380 delay was again observed similar to our genetic studies in both cell lines (Fig. 6D , *p < 381 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001). Our findings suggest that anti-SEMAC 382 treatment may prove valuable for combating osteosarcoma tumor growth, progression, 383 and ultimately lung metastasis through disruption of oncogenic SEMA4C signaling (Fig.  384   6E) . 385 386
Discussion 387
Our studies provide several new insights into the functions of the semaphorin 4C 388 (SEMA4C) signaling pathway promoting osteosarcoma progression and metastasis. 389 SEMA4C has been shown to be highly expressed relative to control tissues and cell lines. 390
Its heightened expression and signaling through its cognate receptor PLXNB2 correlates 391 to patient outcomes in some solid cancers [30] . Our results demonstrate high level 392
cytoplasmic/membraneous SEMA4C expression in malignant primary patient tissues 393 which suggests SEMA4C is targetable on the cell surface. Activation of PLXNB2 signaling 394 by its ligand SEMA4C is likely to occur via autocrine mechanisms in co-expressing tumor 395 cells and via paracrine signaling when PLXNB2 is stimulated from SEMA4C-producing 396 cells in the microenvironment. Our study demonstrates that both normal osteoblasts and 397 osteosarcoma cell lines indeed express both soluble SEMA4C and cognate receptor 398 PLXNB2, but interestingly membrane-bound SEMA4C was only found to be detectable in 399 osteosarcoma cell lines. This data supports both autocrine and paracrine capabilities, but 400 at an exaggerated level similar to previous findings in tumor-associated lymphatic 401 endothelial cells and breast cancer [14, 27] . These elevated levels suggest that 402 osteosarcoma cells are also genetically and phenotypically distinct from that of their 403 normal counterparts. 404
Accumulating evidence suggests that SEMA4C-PLXNB2 interactions can promote 405 an oncogenic signaling axis. Recent reports from Gurrapu et al. and Le et al. established 406 that SEMA4C-PLXNB2 signaling promotes cancer cell proliferation, migration, and 407 tumorigenesis in breast and glioma tumor cells respectively [14, 16] . In our study, we 408 demonstrated that SEMA4C directs both 2D and 3D growth in vitro as well as modulates 409 invasive cell motility and adhesion in osteosarcoma. These phenotypes were associated 410 with large perturbations in activated AKT signaling. In particular, genetic silencing of 411 SEMA4C induced G1 cell cycle delay, which has been well-established and linked with changes in PI3K pathway signaling [31] . These in vitro findings were further substantiated 413 by our mouse studies. We injected two SEMA4C knockdown cell lines into mice using a 414
highly relevant orthotopic mouse model of osteosarcoma [24, 25] . SEMA4C knockdown 415 tumor cells exhibited reduced tumor growth, micrometastatic nodule formation, and area. 416
These data indicate a diverse role for SEMA4C in osteosarcoma growth, metastasis, and 417
maintenance. 418
Among the family of SEMA4 members, several recent reports have demonstrated 419 that SEMA4C also regulates EMT [32, 33] . While this phenomenon has been well-420 established in cancers of epithelial origin [34] , the precise and novel roles EMT factors 421 play in a characteristically mesenchymal cancer such as osteosarcoma, remain to be 422 determined. In agreement with other reports in controlling EMT [32, 33] , our results 423 suggest high level SEMA4C expression promotes invasive cell motility, is associated with 424 mesenchymal marker expression, and can be reversed through genetic disruption. 425
Excitingly, TWIST1 was significantly altered in both of our SEMA4C gain-of-function 426 (GOF) and loss-of-function (LOF) studies. Research from Yin and colleagues suggests 427 TWIST1 is associated with poor prognoses in osteosarcoma and can be used as a 428 prognostic indicator of metastatic potency in patients [35] . Moreover, in a study of 206 429 unique bone tumors, TWIST1 expression was one of three markers in a panel that 430 afforded the most sensitive and specific diagnostic utility among varied bone tumor types 431
[36]. TWIST1 is also essential for tumor initiation and maintaining a mesenchymal state 432 in synovial sarcomas [37] . Reactivation of TWIST1 can also promote metastasis in other 433 sarcomas such as Ewing's sarcoma [38] . The continued demonstration of the plasticity of 434 TWIST1 and other mesenchymal markers in maintaining phenotypes associated with 435 many aspects of osteosarcomagenesis, progression, and metastasis has led to the 436 central belief of skeletal cancer stem cells [39, 40] , of which have been just recently 437 identified [41] . High level expression of SEMA4C may help facilitate a hyper-438 mesenchymal state in osteosarcoma and/or even allow a plasticity that contributes to 439 many of the phenotypes our study illustrates, including wound healing [42] , cellular 440 adhesion [43], tumor growth, and metastasis [44] . 441
The findings of our work may be highly relevant to the clinical setting. To date, 442 metastases to the lungs remains the number one cause of osteosarcoma-related death 443
[45]. Our monoclonal antibody blockade studies support the concept of targeting 444 SEMA4C therapeutically. Targeted blockade of SEMA4C-induced signaling appreciably 445 slowed tumor cell proliferation and migration in vitro. These phenotypic changes were 446 again accompanied by G1 cell cycle delay. Together, these data suggest a rationale for 447 SEMA4C blockade as a potential novel treatment option for patients with metastatic 448 osteosarcoma. Recent studies on SEMA4D, a type IV semaphorin member that can also 449 signal through PLXNB2 [46], suggests high level expression restricts tumoricidal immune 450 cells from entering the tumor microenvironment and blunts their activity, however, 451 monoclonal antibody neutralization by an anti-Sema4d antibody (murine: mAb67-2, 452 human: VX15/2503; Vaccinex, Inc.) could restore these deficits in combination with anti-453
Ctla-4 or anti-Pd-1 checkpoint blockade [47] [48] [49] . Likewise, antibody targeting of SEMA4C 454 could be highly advantageous for these same reasons and others we posit here. This 455 could allow expansion of the poor portfolio of therapies available to metastatic 456 osteosarcoma patients and may also be applied to other cancer types in which high 457 SEMA4C expression is clinically relevant. 458 
